focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
The price of US oil has turned negative for the first time in history.
That means oil producers are paying buyers to take the commodity off their hands over fears that storage capacity could run out in May.
Demand for oil has all but dried up as lockdowns across the world have kept people inside.
As a result, oil firms have resorted to renting tankers to store the surplus supply and that has forced the price of US oil into negative territory.
The price of a barrel of West Texas Intermediate (WTI), the benchmark for US oil, fell as low as minus $37.63 a barrel.
“Jabba...I'm a shareholder .....a realistic one.”
Sorry even a someone putting the lotto on wouldn’t shout for different numbers.
Must admit I’m hanging fire, I sold half my holdings abit back to try and get some gains so I could top up here before the agm. Think I will wait till after any clear direction of what is happening, if we get it.
Fingers X
Fingers X
Might explain the recent interest .
https://www.sharesmagazine.co.uk/video/neill-ricketts-ceo-of-versarien-vrs
Edison issues update on Silence Therapeutics (SLN)
The year 2019 marked a major turnaround for Silence, as it both ramped up its development activity, with the advancement of SLN124 for iron overload and SLN360 for cardiovascular disease, and made massive partnering efforts. We have seen the fruits of this business development in the form of three partnering deals with major pharmaceutical companies Mallinckrodt, Takeda and AstraZeneca. Together all these efforts demonstrate the value of the company's siRNA platform and intellectual property.
Our valuation for Silence is largely unchanged at £461.2m or 558p/share, following a slight adjustment of less than £1m (£461.9m or 559p previously). This adjustment is due to slightly lower expected revenue from the Onpattro royalty stream, based on the company's reports (£73k in 2019). We expect the company to require £85m (up from £80m, and recorded in 2023) in additional capital to reach profitability in 2027.
The big caveat in using directors dealings is that you need to be fairly long term in your outlook when using them as a criterion for investing. Directors are limited as to when they can legally buy and sell shares. They cannot trade between the closing of the financial period and the reporting to the market of that information, often two months later. Companies report at least twice yearly, sometimes quarterly, so the dealing ‘window’ available to directors is oftentimes very narrow, and not necessarily the optimum time, price wise, to buy or sell shares.
National, regional and local newspapers are under huge financial pressure, largely because of plummeting commercial advertising on their printed pages and websites.
https://news.sky.com/story/coronavirus-brits-urged-to-buy-a-paper-as-industry-grapples-with-biggest-ever-crisis-11975128
The findings of this study demonstrate that Bidstack's in-game format is a powerful way for brands to reach their target audience. Bidstack outperformed multiple traditional ad channels, in some cases by as much as 11x. We were impressed not only with the attention the ads received, but more importantly with the strong brand recall and the positive impact on brand perceptions that the ads generated."
Ha tickled me that, 4 speeding tickets. All the years I’ve spent on lse that’s the first time I’ve heard them called that.
Same again tomorrow please.
Got more chance of making multiple gains here now, rather than ncyt. Easy possibility of this reaching a quid over the next few weeks with what news is due. Just buy and be patient.
Wouldn’t of thought so, it’s not widely known what they are doing as the amount of trades show. Slightly under the radar but will surface soon enough.
Was thinking that, seems they want the cash. Will bounce very sharply this tomorrow.
In November 2019, Ygen opened its state-of-the-art facility at Citylabs, in the centre Manchester’s £95m genomics campus. This GMP (Good Manufacturing Practice) facility has un-used capacity, which would have been slowly filled by Ygen’s own growing requirements, but it is well prepared to scale-up as it anticipates ramping-up production.
The Citylabs facility is a key part of the ongoing integration of the £8.9m Elucigene acquisition which was completed in April 2019. The consolidation into a single management structure and manufacturing facility is already generating efficiencies. The four strategic priorities are product penetration, geographic and product expansion and acquisitive growth with earning enhancing deals.
One of the factors in the accelerated organic growth at the Interims was the increased product penetration for the flagship non-invasive prenatal tests (NIPT) for Down’s syndrome and other genetic disorders, and an expansion of its oncology and research services activity. The sales footprint has been expanded as it now sells products into over 60 countries worldwide, compared to 30 countries.
The US is a target for expansion and corporate activity can be anticipated. The COVID -19 tests will accelerate utilization of the new capacity and the company’s profitability.
Financials
In April 2019, an over-subscribed fund raising at 10.25p a share raised nearly £12m. After the acquisition and investment in the new facility the net cash is around £3.6m.
Trading Strategy
At a near £100m market cap a moderate upgrade seems anticipated, the risk from here however seems to be missing the Covid -19 assisted upside.
Buy
Will be along shortly, and when it does it will follow the likes of the ncyt,gdr.
Getting a few profit takers around the 6 level but once they are cleared it’s the next leg up, could be this afternoon.
With only a small amount of trades and this rise.... word gets out this will see a substantial re rate.
Ouch, that’s a big spread.
Hahaha
Well if their Basic questions and you can’t answer them yourself, you are as daft as you sound.
If you have so much concern why you even asking, or here.
Smart person would be looking somewhere else for a money maker.
You are a muppet.
And it’s easy to see what you are trying to do.
Repeating yourself ain’t getting you no where.
WE’VE HEARD IT ALL BEFORE....
And I thought fishing was only fun outside, seems there’s a lot of bottom feeders on line too. Soo easy with the right bait lol.
These challenges are reflected in Bidstack’s share price, which has plunged more than 60 per cent in the last six months (though this has begun to reverse since the coronavirus outbreak).
Boss Draper seems unconcerned about the turbulent trading, which he blames on “a bunch of interesting shorters and pain in the arse people on Aim”.
Bidstack is yet to generate significant revenue, but Draper says there is no immediate need to raise more cash. The firm has tapped former Playstation chief Andrew House in an advisory role, and is pinning its hopes on a future breakthrough for the ad format.
Ultimately, the goal is to capitalise on the esports market. If advertisers can target the people watching gamers — rather than just the gamers themselves — they can expand their reach exponentially.
“To get to the point where we can interchange the adverts based on the secondary [audience] without causing any latency whatsoever to the stream, that is an absolute goldmine,” says Draper.
https://www.cityam.com/long-read-advertisers-look-to-esports-as-gamers-flock-to-virtual-stadia/